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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
• To determine the diagnostic accuracy of TcB as:
i) a diagnostic test for hyperbilirubinaemia in newborns suspected to have hyperbilirubinaemia on visual inspection;
ii) a diagnostic test for monitoring bilirubin levels in newborns receiving treatment (e.g. phototherapy) for
hyperbilirubinaemia.
1. a diagnostic test for hyperbilirubinaemia in newborns suspected to have hyperbilirubinaemia on visual inspection;
2. a diagnostic test for monitoring bilirubin levels in newborns receiving treatment (e.g. phototherapy) for hyperbilirubinaemia.
• To determine whether the gestational age, postnatal age, body weight, race and site of TcB measurement have any influence on
the accuracy of TcB measurement for hyperbilirubinaemia in newborns.
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B A C K G R O U N D
Target condition being diagnosed
Hyperbilirubinaemia is a term used to describe excess of bilirubin
in the blood. In newborns, hyperbilirubinaemia becomes clini-
cally apparent as jaundice, a yellow colouration of the skin and
sclera (Woodgate 2015). Hyperbilirubinaemia is very common
in both term and preterm newborn infants (occurring in about
60% of newborns) and results from a predisposition to the pro-
duction of bilirubin and their limited ability to excrete it (Lauer
2011). Most cases of newborn jaundice are mild and resolve spon-
taneously (Srgo 2006). However, in rare cases babies can have very
high levels of bilirubin that can lead to bilirubin encephalopathy
and kernicterus (Ebbesen 2005; Srgo 2006). The acute phase signs
of kernicterus are poor feeding, lethargy, high-pitched cry, hyper-
tonia or hypotonia, opisthotonos and seizures (Johnson 2002).
The chronic manifestations include athetoid cerebral palsy, mo-
tor delay, gaze palsy, dental dysplasia, mental retardation and sen-
sorineural hearing loss (AAP 2004). Studies from developed coun-
tries estimate the incidence of kernicterus to range from about
0.4 to 2 per 100,000 (Srgo 2006; Mannig 2007; Burke 2009).
However, studies from developing countries suggest that the in-
cidence may be much higher (Nair 2003; Owa 2009). Following
guidelines issued by the American Academy of Pediatrics for the
management of jaundice in the neonate (AAP 2004), the age-long
critical cut-off value of total serum bilirubin (TsB) of 20 mg/dL
(342 µmol/L) at which therapy was required is being replaced by
a plot of TsB against time (hours) for each baby. This is compared
to the nomogram for the age of the baby and used to determine
the line of management (Higgins 2012). Current treatments for
hyperbilirubinaemia include phototherapy and exchange transfu-
sion, which is usually used for severe cases of hyperbilirubinaemia
(Woodgate 2015).
Index test(s)
Transcutaneous bilirubin (TcB) measurement is a non-invasive
method for measuring serum bilirubin level (Dai 1997). Tran-
scutaneous bilirubinometry works by directing light into the skin
and measuring the intensity of the wavelength of light that is re-
turned (Boo 2007). Transcutaneous bilirubinometry is based on
optical spectroscopy, which relates the amount of light absorption
by bilirubin to the concentration of bilirubin in the skin. The
technology was first introduced in 1980 (Yamanouchi 1980). The
measurement is usually taken by gently pressing the meter against
the sternum or forehead. Transcutaneous bilirubin measurement
provides an immediate (less than a minute) result of bilirubin lev-
els (Dai 1997). Using this point-of-care device saves time com-
pared to measuring serum bilirubin and may reduce costs associ-
ated with measuring serum bilirubin in newborns (Maisels 1997).
However, the accuracy of TcB results may be affected by gesta-
tional age, body weight and skin colour (Knüpfer 2001; Karen
2009). For example, TcB tends to underestimate TSB in light
and medium skin colours and overestimates in dark skin colour
(Samiee-Zafarghandy 2014). There are a number of TcB devices
available, including the Bilicheck device, JM 103 and JM 105 de-
vices (Grohmann 2006).
Clinical pathway
Newborns are routinely monitored by nursing staff and physi-
cians for the development of jaundice in the first few hours of life
and before discharge from the newborn nursery. This is usually
done by visual inspection and skin blanching to assess for yel-
lowish discolouration. Visual estimation of bilirubin level is not
reliable (Barrington 2012). Therefore, bilirubin level needs to be
assessed objectively by means of a TcB or TsB measurement. In
some settings, TcB or TsB measurements are performed on all
newborns as part of routine screening before hospital discharge or
as targeted screening based on risk factors for severe hyperbiliru-
binaemia. Some of the risk factors include breastfeeding, ABO/
Rhesus incompatibility, glucose-6-phosphate dehydrogenase defi-
ciency, use of oxytocin during delivery, vacuum-assisted delivery,
prematurity, and history of jaundice in a sibling (AAP2004; Keren
2005; Bhutani 2010). TcB or TsB measurement can be done as
part of universal screening or only if a newborn is visibly jaun-
diced and the value is plotted on a nomogram to assess the need
for treatment (AAP 2004). In addition, the measurements may be
taken on newborns undergoing phototherapy to help in making
a decision on when to stop treatment. The bilirubin levels are in-
terpreted based on the infant’s gestational age and postnatal age
(AAP 2004).
Role of index test(s)
The TcB assay is a non-invasive method for measuring bilirubin
levels and it may help to reduce the risk of anaemia and trauma
associated with blood sampling for TsB measurement (Dai 1997).
TcB has been shown to work well in both hospital and outpa-
tient settings; and has been shown to be better than visual inspec-
tion for estimation of hyperbilirubinemia (De Luca 2008; Wainer
2012). Additionally, the TcB measurement ensures a readily avail-
able result for immediate clinical decision-making while reducing
the chances of infections associated with all invasive procedures
(Jangaard 2006). The TcB meter can be used as a screening tool
to estimate the serum bilirubin level in newborns who are not
clinically jaundiced or as a diagnostic tool in jaundiced newborns
to assess the need for treatment (AAP 2004).
Alternative test(s)
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Various methods are used to determine bilirubin levels in new-
borns. These include visual assessment, direct spectrophotomet-
ric methods (requiring capillary blood) and use of an icterome-
ter (Higgins 2012). Visual assessments for jaundice are common
in newborn nurseries and outpatient settings, such as physicians’
offices (Harrison 1989). However, studies have shown that the
severity of jaundice cannot be assessed through visual estimation.
The icterometer is a specialized ruler marked with different shades
of yellow used to estimate the bilirubin level when pressed against
a newborn’s skin (Akman 2000).
Rationale
Bilirubin measurement is one of the most frequently performed
tests in newborn infants (Donzelli 2000; Madsen 2000). Chemi-
cal methods for serum bilirubin measurement is currently the ref-
erence standard for measuring bilirubin levels. However, this re-
quires repeated blood sampling which can be painful to the new-
born, costly and time consuming. Transcutaneous bilirubin mea-
surement has been recommended as a more cost-effective and less
traumatic method of measuring bilirubin levels in newborns (Dai
1996). In order to justify routine use of TcB devices, we need to
systematically review all the available evidence from well-designed
studies on the accuracy of TcB measurements in newborn infants.
A clear understanding of the diagnostic test accuracy of transcu-
taneous bilirubinometry using a variety of instruments in a vari-
ety of populations (including preterm and term infants as well as
infants with various racial backgrounds) would be invaluable for
understanding the usefulness of TcB measurement in newborns.
O B J E C T I V E S
• To determine the diagnostic accuracy of TcB as:
i) a diagnostic test for hyperbilirubinaemia in newborns
suspected to have hyperbilirubinaemia on visual inspection;
ii) a diagnostic test for monitoring bilirubin levels in
newborns receiving treatment (e.g. phototherapy) for
hyperbilirubinaemia.
• To determine whether the gestational age, postnatal age,
body weight, race and site of TcB measurement have any
influence on the accuracy of TcB measurement for
hyperbilirubinaemia in newborns.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include diagnostic test accuracy studies comparing TcB
and TsB measurement for hyperbilirubinaemia in newborns, as
follows.
• Cross-sectional studies.
• Cohort studies.
Wewill exclude all randomised controlled trials, retrospective stud-
ies, case-control studies, case reports and any studies in which data
for true positives, true negatives, false positives and false negatives
cannot be determined. Retrospective studies will also be excluded.
Participants
We will include studies evaluating infants aged 0 to 29 days (in-
cluding term or preterm newborns) who require bilirubin mea-
surement either as a universal screening test or a test for visible
jaundice or for monitoring therapy for hyperbilirubinaemia. We
will include studies conducted in different patient settings such as
neonatal intensive care units, paediatric emergency units, paedi-
atric wards and studies that recruited participants from home or
in the communities.
Index tests
We will include studies that assessed the accuracy of any TcB
device in newborns.
Target conditions
The target condition is hyperbilirubinaemia requiring treatment
either by phototherapy or by exchange transfusion.
Reference standards
The reference standard is TsB measured in the laboratory, which
requires blood sampling from the newborn. TsB measurement can
be performed in the laboratory using various methods such as high
performance liquid chromatography (HPLC), Diazo-based meth-
ods, or other methods such as direct spectrophotometric methods
(Kazmierczak 2002) and capillary electrophoresis (Higgins 2012).
Total serum bilirubin measurement by the HPLC method is not
subject to interference from haemoglobin or lipaemia. However,
this method is costly, labour-intensive and not practical for rou-
tine use (Kazmierczak 2004). The Diazo-based methods are the
most frequently used laboratory assays but may be affected by
haemolysis (el-Beshbishi 2009). Total serum bilirubin measure-
ment requires drawing of blood causing pain and trauma to the
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neonate. Repeated blood sampling for TsBmeasurement can cause
anaemia, especially in preterm neonates. Inter- and intralabora-
tory variability has been reported with measurements of TsB (Lo
2011).
Search methods for identification of studies
We will use the standard search strategy of the Cochrane Neonatal
ReviewGroup to identify all relevant studies without any language
restriction. Methodological filters for diagnostic studies will not
be used, to avoid missing out on some relevant studies. We will
attempt to get translation for articles written in languages other
than English. We will record any article for which we could not
get a translation in the section ’Characteristics of studies awaiting
classification’.
Electronic searches
We will search the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library.
• MEDLINE Ovid (from 1966).
• Embase Ovid SP (from 1982).
• CINAHL (via EBSCOhost) (from 1982).
We will also search the following trial registries.
• ClinicalTrials.gov
• International Standard Randomised Controlled Trial
Number (ISRCTN) registry (www.isrctn.com/)
• World Health Organization (WHO) International Clinical
Trials Platform (ICTRP) Search portal (apps.who.int/
trialsearch/).
There will be no date restrictions in the search of trial registries.
Our search strategy for Embase was developed by discussion be-
tween the author team and the Cochrane Neonatal Group’s Tri-
als Search Co-ordinator (Appendix 1). We will adapt it for use in
other databases.
We will also conduct searches based on the Embase strategy to
identify other potential studies in:
• DARE (Database of Abstracts of Reviews of Effects);
• MEDION database (for Systematic Reviews of Diagnostic
Studies).
We will screen the reference lists of any relevant reviews from
DARE and MEDION for potentially eligible studies.
Searching other resources
We will examine the references lists of all included studies for
possible additional studies.
Data collection and analysis
Selection of studies
Two review authors will independently assess eligible articles for
inclusion from the titles and abstracts obtained in the initial search.
They will resolve any disagreement through discussion or, if nec-
essary, by involving a third review author.
Data extraction and management
Two review authors will independently extract data on study char-
acteristics using a standard data extraction form.We will compute
2 × 2 tables of true positives, false positives, true negatives and false
negatives, for the index tests at the thresholds reported. Where
reported, we will exclude undetermined or indefinite results from
the analyses. We will discuss differently extracted data until con-
sensus is reached. The information we will extract from each study
is presented in Table 1.
Assessment of methodological quality
Two of the authors will independently assess the methodological
quality of each included study using theQuality Assessment of Di-
agnostic Accuracy Studies-2 (QUADAS-2) tool (Whiting 2011),
which consists of four domains. We will develop a rating guideline
for assessment of the domains in order to ensure consistency. We
will assess each of the four domains with respect to the risk of
bias. Additionally, we will assess the first three domains in terms
of applicability.We will pilot our review-specific QUADAS-2 tool
against five primary studies in order to identify possible areas of
discrepancies between authors. We will make modifications to the
tool if possible, to ensure consistency.Wewill resolve discrepancies
in assessments between review authors by consensus. If this is im-
possible, wewill seek final resolution using a third-party arbitrator.
The items of the QUADAS-2 tool and our scoring interpretations
for each item are presented in Appendix 2.
Statistical analysis and data synthesis
We will perform statistical analysis according to Cochrane guide-
lines for diagnostic test accuracy (DTA) reviews (Macaskill 2010).
We will include studies reporting sufficient data that allows for
the construction of a 2 × 2 table and also studies that only re-
ported the Pearson correlation coefficients to describe the relation-
ship between TcB and TsB measurements. The data from the 2
× 2 tables will be used to calculate sensitivity and specificity for
each study and also meta-analysis of sensitivities and specificities
where appropriate using the bivariate model if the same thresh-
old for positivity was used. According to the bivariate method
we will calculate overall sensitivity and specificity and their 95%
confidence intervals (CIs), based on the binomial distributions of
the true positives and true negatives (Reitsma 2005). However,
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we anticipate that studies will use multiple thresholds, both be-
tween studies and within individual studies. If data with more
than one positive threshold is reported within a study, we will ex-
tract the relevant data and present the findings graphically for each
threshold. We will perform meta-analysis with the most common
threshold where appropriate; and fit a summary receiver operat-
ing characteristic (ROC) curve using a bivariate random-effects
model (Reitsma 2005). We will use the latest version of the Re-
view Manager (RevMan) software to graphically present coupled
forest plots, showing the pairs of sensitivity and specificity (and
their 95% CIs) of each study, for each threshold. We will also
present coupled forest plots of the Pearson correlation coefficients
across studies where relevant, to allow basic visual inspection of
individual studies only. All indefinite results will be excluded from
the analysis.
Investigations of heterogeneity
The investigation of heterogeneity will be performed through vi-
sual examination of both the ROC plot of raw data and the forest
plots of sensitivities and specificities. We will formally investigate
potential sources of heterogeneity other than threshold effect in
bivariate models if we have a sufficient number of studies. By fit-
ting the covariates in a bivariate regression model, we will investi-
gate the following sources of heterogeneity in the diagnostic per-
formance across studies: type of TcB meter; gestational age (term
versus preterm infants); race or skin colour; prior use of photother-
apy; and reference standard. We will investigate the effect of these
covariates by conducting subgroup analyses in the latest version of
the RevMan software and by including each of these factors as co-
variates in the bivariate regression model. A minimum of 10 stud-
ies will be needed per covariate included in the regression model.
Sensitivity analyses
We will perform sensitivity analyses on the different domains
scored on the QUADAS-2 tool, in order to explore the influence
of the quality of the included studies. We will perform additional
sensitivity analyses if other suitable factors are identified during
the review process and any such analysis will be reported as ’post
hoc’ in the final review.
Assessment of reporting bias
We are not planning to use funnel plots to evaluate the impact of
publication bias or other biases associated with small studies.
R E F E R E N C E S
Additional references
AAP 2004
American Academy of Pediatrics, Subcommittee on
Hyperbilirubinemia. Management of hyperbilirubinemia
in the newborn infant 35 or more weeks of gestation.
Pediatrics 2004;114(1):297-316. [PUBMED: 15231951]
Akman 2000
Akman I, Arika Ç, Bilgen H, KalaCa S, Özek E.
Transcutaneous Measurement of Bilirubin by Icterometer
During Phototherapy on a Bilibed. Turkish Journal of
Medical Sciences 2000;32:165–8.
Barrington 2012
Barrington KJ, Sankaran K. Canadian Paediatric Society;
Fetus and Newborn Committee. Guidelines for detection,
management and prevention of hyperbilirubinemia in term
and late preterm newborn infants. Paediatric Child Health
2007;12(Suppl B):1B–12B.
Bhutani 2010
Bhutani VK, Vilms RJ, Hamerman-Johnson L. Universal
bilirubin screening for severe neonatal hyperbilirubinemia.
Journal of Perinatology 2010;30 Suppl:S6–15. [PUBMED:
20877410]
Boo 2007
Boo NY, Ishak S. Prediction of severe hyperbilirubinaemia
using the Bilicheck transcutaneous bilirubinometer. Journal
of Paediatrics and Child Health 2007;43(4):297–302. [DOI:
10.1111/j.1440-1754.2007.01062.x]
Burke 2009
Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C,
Tilford JM. Trends in hospitalizations for neonatal jaundice
and kernicterus in the United States, 1988-2005. Pediatrics
2009;123(2):524–32. [PUBMED: 19171618]
Dai 1996
Dai J, Krahn J, Parry DM. Clinical impact of
transcutaneous bilirubinometry as an adjunctive screen
for hyperbilirubinemia. Clinical Biochemistry 1996;29(6):
581–6. [PUBMED: 8939407]
Dai 1997
Dai J, Parry DM, Krahn J. Transcutaneous bilirubinometry:
its role in the assessment of neonatal jaundice. Clinical
Biochemistry 1997;30(1):1–9. [DOI: 10.1016/S0009-9120
(96)00131-2]
De Luca 2008
De Luca D, Zecca E, Zuppa AA, Romagnoli C. The joint
use of human and electronic eye: visual assessment of
jaundice and transcutaneous bilirubinometry. Turkish
Journal of Pediatrics 2008;50(5):456–61.
Donzelli 2000
Donzelli G, Pratesi S. Transcutaneous bilirubinometry in
healthy preterm newborns. Clinical Biochemistry 2000;33
(6):505–8. [PUBMED: 11074244]
Ebbesen 2005
Ebbesen F, Andersson C, Verder H, GrytterC, Pedersen-
Bjergaard L, Petersen JR, et al. Extreme hyperbilirubinaemia
5Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in term and near-term infants in Denmark. Acta Paediatrica
2005;94(1):59–64. [PUBMED: 15858962]
el-Beshbishi 2009
el-Beshbishi SN, Shattuck KE,Mohammad AA, Petersen JR.
Hyperbilirubinemia and transcutaneous bilirubinometry.
Clinical Chemistry 2009;55(7):1280–7. [PUBMED:
19443565]
Grohmann 2006
Grohmann K, Roser M, Rolinski B, Kadow I, Müller
C, Goerlach-Graw A, et al. Bilirubin measurement for
neonates: comparison of 9 frequently used methods.
Pediatrics 2006;117(4):1174–83. [DOI: 10.1542/
peds.2005-0590]
Harrison 1989
Harrison SP, Barlow IM. Three direct spectrophotometric
methods for determination of total bilirubin in neonatal and
adult serum, adapted to the Technicon RA-1000 analyzer.
Clinical Chemistry 1989;35(9):1980–6. [PUBMED:
2776331]
Higgins 2012
Higgins T, Eckfeldt JH, Barton JC, Doumas BT.
Hemoglobin, iron and bilirubin. In: Burtis CA, Ashwood
ER, Bruns DE editor(s). Tietz textbook of clinical chemistry
and molecular diagnostics. 4th Edition. Missouri: Elsevier
Saunders, 2012:985–1030.
Jangaard 2006
Jangaard K, Curtis H, Goldbloom R. Estimation of
bilirubin using BiliChektrade mark, a transcutaneous
bilirubin measurement device: Effects of gestational age and
use of phototherapy. Paediatrics & Child Health 2006;11
(2):79–83.
Johnson 2002
Johnson LH, Bhutani VK, Brown AK. System-based
approach to management of neonatal jaundice and
prevention of kernicterus. Journal of Pediatrics 2002;140
(4):396–403.
Karen 2009
Karen T, Bucher HU, Fauchère JC. Comparison of a
new transcutaneous bilirubinometer (Bilimed® ) with
serum bilirubin measurements in preterm and full term
infants. BMC Pediatrics 2009;9:70. [DOI: 10.1186/
1471-2431-9-70]
Kazmierczak 2002
Kazmierczak SC, Robertson AF, Catrou PG, Briley KP,
Kreamer BL, Gourley GR. Direct spectrophotometric
method for measurement of bilirubin in newborns:
comparison with HPLC and an automated diazo method.
Clinical Chemistry 2002;48(7):1096–7. [PUBMED:
12089180]
Kazmierczak 2004
Kazmierczak SC, Robertson AF, Briley KP, Kreamer B,
Gourley GR. Transcutaneous measurement of bilirubin
in newborns: comparison with an automated Jendrassik-
Grof procedure and HPLC. Clinical Chemistry 2004;50(2):
433–5. [PUBMED: 14752014]
Keren 2005
Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A,
Schwartz JS. Identifying newborns at risk of significant
hyperbilirubinaemia: a comparison of two recommended
approaches. Archives of Disease in Childhood 2005;90(4):
415–21. [DOI: 10.1136/adc.2004.060079]
Knüpfer 2001
Knüpfer M, Pulzer F, Braun L, Heilmann A, Robel-
Tillig E, Vogtmann C. Transcutaneous bilirubinometry in
preterm infants. Acta Paediatrica 2001;90:899–903. [DOI:
10.1080/08035250152509636]
Lauer 2011
Lauer BJ, Spector ND.Hyperbilirubinemia in the Newborn.
Pediatrics in Review. Pediatrics in Review 2011;32(8):
341–9. [PUBMED: 21807875]
Lo 2011
Lo SF, Doumas BT. The status of bilirubin measurements
in U.S. laboratories: why is accuracy elusive?. Seminars in
Perinatology 2011;35(3):141–7. [PUBMED: 21641487]
Macaskill 2010
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi
Y. Chapter 10: Analysing and Presenting Results. In: Deeks
JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy Version
1.0. The Cochrane Collaboration, 2010. Available from
srdta.cochrane.org.
Madsen 2000
Madsen LP, Rasmussen MK, Bjerregaard LL, Nohr SB,
Ebbesen F. Impact of blood sampling in very preterm
infants. Scandinavian journal of clinical and laboratory
investigation 2000;60(2):125–32. [PUBMED: 10817399]
Maisels 1997
Maisels MJ, Kring E. Transcutaneous bilirubinometry
decreases the need for serum bilirubin measurements and
saves money. Pediatrics 1997;99:599–601.
Mannig 2007
Manning D, Todd P, Maxwell M, Platt M. Prospective
surveillance study of severe hyperbilirubinaemia in the
newborn in the UK and Ireland. Archives of Disease in
Childhood. Fetal and Neonatal Edition 2007;92(5):342–6.
[PUBMED: 17074786 ]
Nair 2003
Nair PA, Al Khusaiby SM. Kernicterus and G6PD
deficiency--a case series from Oman. Journal of Tropical
Pediatrics 2003;49(2):74–7. [PUBMED: 12729287]
Owa 2009
Owa JA, Ogunlesi TA. Why we are still doing so many
exchange blood transfusion for neonatal jaundice in Nigeria.
World Journal of Pediatrics 2009;5(1):51–5. [PUBMED:
19172333]
Reitsma 2005
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt
PM, Zwinderman AH. Bivariate analysis of sensitivity and
specificity produces informative summary measures in
6Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
diagnostic reviews. Journal of Clinical Epidemiology 2005;
58(10):982–90. [PUBMED: 16168343]
Samiee-Zafarghandy 2014
Samiee-Zafarghandy S, Feberova J, Williams K, Yasseen AS,
Perkins SL, Lemyre B. Influence of skin colour on diagnostic
accuracy of the jaundice meter JM 103 in newborns.
Archives of Disease in Childhood. Fetal and Neonatal Edition
2014;99(6):F480–4.
Srgo 2006
Sgro M, Campbell D, Shah V. Incidence and causes of severe
neonatal hyperbilirubinemia in Canada. Canadian Medical
Association Journal 2006;175(6):587–90. [PUBMED:
16966660]
Wainer 2012
Wainer S, Parmar SM, Allegro D, Rabi Y, Lyon ME. Impact
of a transcutaneous bilirubinometry program on resource
utilization and severe hyperbilirubinemia. Pediatrics 2012;
129(1):77–86.
Whiting 2011
Whiting PF, Rutjes AW, Westwood ME, Mallett S, DeeksJJ,
Reitsma JB, et al. QUADAS-2: a revised tool for the quality
assessment of diagnostic accuracy studies. Annals of Internal
Medicine 2011;155(8):529-36. [PUBMED: 22007046]
Woodgate 2015
Woodgate P, Jardine LA. Neonatal jaundice: phototherapy.
(Systematic review 319. BMJ Clinical Evidence).
www.clinicalevidence.bmj.com/x/systematic-review/0319/
overview.html (accessed 22 February 2016).
Yamanouchi 1980
Yamanouchi I, Yamauchi Y, Igarashi I. Transcutaneous
bilirubinometry: preliminary studies of noninvasive
transcutaneous bilirubin meter in the Okayama National
Hospital. Pediatrics 1980;65(2):195–202. [PUBMED:
7354964]
∗ Indicates the major publication for the study
A D D I T I O N A L T A B L E S
Table 1. Data from each study
[Study ID] First author, year of publication
Type of study Journal article, unpublished data
Participants Sample size
Country of study
Baseline characteristics (gestational age, postnatal age, race, body weight)
Study design Retrospective/prospective design
Sample (consecutive, random or unclear)
Study criteria Inclusion criteria
Exclusion criteria
Reference standard Name of assay/manufacturer
Name of instrument
Cut-off values
Time between reference standard performance and TcB measurement
Blinding of operator to TcB result
Index test Name of device
Cut-off values
Operator training
site of measurement (forehead, sternum)
Target condition Universal screening of newborns for hyperbilirubinaemia
Diagnostic determination of hyperbilirubinaemia in visibly jaundiced newborns
Monitoring of bilirubin in newborns on therapy for hyperbilirubinaemia
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Table 1. Data from each study (Continued)
Data Number of true positives and false positives
Number of true negatives and false negatives
Number of undetermined/uninterpretable results
Sensitivity and specificity of index test
Number of missing results for index test
Number of missing results for reference standard
Notes Source of funding (whether any author is affiliated with the manufacturer of the index test; the study was
directly funded by the manufacturer; authors reported conflicts of interests related to the manufacturer or other
funding sources)
A P P E N D I C E S
Appendix 1. Embase search strategy
Our search strategy for Embase OVID below was developed by discussion between the author team and the Cochrane Neonatal Group’s
Trials Search Co-ordinator. We will adapt it for use in other databases.
(infant, newborn or neonat* or premature or very low birth weight or low birth weight or VLBW or LBW or infan*) AND ((transcu-
taneous adj2 bilirubin) OR TcB OR bilicheck OR bilichek OR JM-103 OR JM-105 OR bilirubinomet* AND ((blood* or serum) adj
bilirubin) OR TsB OR spectrophotomet*).mp
Appendix 2. QUADAS-2 tool
QUADAS-2 tool: Risk of bias and applicability judgements
Domain 1: Patient selection Domain 1: Patient
A. Risk of bias
1.Was a consecutive or random sample of patients enrolled? Yes/No/Unclear
“Yes” if it is clearly stated in the paper that a consecutive or a
random sample of patients was enrolled
“No” if the patients were not recruited consecutively or the sample
was not random
“Unclear” if there is insufficient information to answer “yes” or
“no”
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(Continued)
2.Was a case-control design avoided? Yes/No/Unclear
The answer will always be “yes” since the review will exclude case-
control studies
3. Did the study avoid inappropriate exclusions? Yes/No/Unclear
“Yes” if the stated inclusion and exclusion criteria are clear and
appropriate
“No” if the stated inclusion and exclusion criteria include inap-
propriate subjects
“Unclear” if insufficient information is available to answer “yes”
or “no”
4.Could the selection of patients have introduced bias? RISK: Yes/No/Unclear
“No” if questions 1 and 3 are answered “yes” (Low risk).
“Yes” if questions 1 or 3 is answered “no” (High risk).
“Unclear” if insufficient information is available to answer ques-
tions 1 or 3
B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting): Describe included
use of index test
1. Is there concern that the included patients do not match
the review question?
CONCERN: Yes/No/Unclear
“No” when the study population represents an unselected sample
of newborns expected to receive TcB assessment for hyperbiliru-
binaemia (Low)
“Yes” if included patients are inherently different from those ex-
pected to receive TcB assessment for hyperbilirubinaemia (High)
“Unclear” if there is insufficient information tomake a judgement
on the patient inclusion (Unclear)
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) Domain 2: Index
please complete for
A. Risk of bias
Describe the index test and how it was conducted and interpreted: Describe the index
preted:
1.· Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes/No/Unclear
“Yes” if the paper states that the index test is interpreted by indi-
vidual(s) who were unaware of the results of the reference test(s)
“No” if the results of the index test were known by the individuals
performing the reference test, or if the same individual performed
both tests
“Unclear” if there is insufficient information to answer “yes” or
“no”
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(Continued)
2. If a threshold was used, was it pre-specified? Yes/No/Unclear
“Yes” if a pre-specified positivity threshold was stated.
“No” if a threshold was not pre-specified.
“Unclear” if there is insufficient information to answer “yes”or
“no”
3.Could the conduct or interpretation of the index test have
introduced bias?
RISK: Low/High/Unclear
“No” if questions 1 and 2 are answered’“yes” (Low risk).
“Yes” if questions 1 or 2 is answered “no” (High risk).
“Unclear if there is insufficient information available to answer
“yes” or “no” (Unclear risk)
B. Concerns regarding applicability
Is there concern that the index test, its conduct, or interpre-
tation differ from the review question?
CONCERN: Low/High/Unclear
“No” if there are no concerns based on the information available
(Low)
“Yes” if the index test is not TcB measurement for hyperbilirubi-
naemia in newborns or if the conduct of the test or its interpreta-
tion is not applicable to the review question (High)
“Unclear” if there is insufficient information to answer “yes” or
“no”
Domain 3: Reference standard Domain 3: Refer
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted: Describe the refer
interpreted:
1 Is the reference standard likely to correctly classify the target
condition?
Yes/No/Unclear
“Yes” if the reference standard is TsB measured by one of the
laboratory methods mentioned in this protocol
“No” if the above condition is not met.
“Unclear” if there is insufficient information to answer “yes” or
“no”
2 Were the reference standard results interpreted without
knowledge of the results of the index test?
Yes/No/Unclear
“Yes” if it is stated that the individual performing/interpreting the
results of the reference standard was kept unaware of the results
of the index test
“No” if the results of the TcB measurement were known to the
individual performing/interpreting the reference standard
“Unclear” if there is insufficient information to answer “yes” or
“no”
Could the reference standard, its conduct, or its interpretation
have introduced bias?
RISK: Low/High/Unclear
“No” if questions 1 and 2 are answered “yes” (Low risk).
“Yes” if question 1 or 2 is answered “no” (High risk).
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(Continued)
“Unclear” if there is insufficient information to answer “yes” or
“no”
B. Concerns regarding applicability
Is there concern that the target condition as defined by the
reference standard does not match the review question?
CONCERN: Low/High/Unclear
“No” if the target condition is hyperbilirubinaemia in newborns
(Low)
“Yes” if the target condition is not hyperbilirubinaemia in new-
borns or it is not clearly stated (High)
“Unclear” if there is insufficient information available to answer
“yes”or “no” (Unclear)
Domain 4: Flow and timing Domain 4: Flow
A. Risk of bias
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table
(refer to flow diagram):
Describe the time interval and any interventions between index test(s) and reference standard:
Describe any patients
or reference standar
(refer to flow diagram):
Describe the time
test(s) and reference
1.·Was there an appropriate interval between index test(s) and
reference standard?
Yes/No/Unclear
“Yes” if the time between the index test and the reference standard
is less than 30 minutes
“No” if the time between the index test and the reference stan-
dard is longer than 30 minutes for a significant proportion of the
patients
“Unclear” if insufficient information is available to answer “yes”
or “no”
·2. Did all patients receive a reference standard? Yes/No/Unclear
“Yes” if all the patients who received the index test received a
reference standard
“No” if not all the patients who received the index test received a
reference standard
“Unclear” if there is insufficient information to answer “yes” or
“no”
·3. Did patients receive the same reference standard? Yes/No/Unclear
“Yes” if the same reference standard was used for all patients
“No” if different reference standards were used.
“Unclear” if there is insufficient information to answer “yes” or
“no”
4.· Were all patients included in the analysis? Yes/No/Unclear
“Yes”if all patients were included in the analysis,or if any with-
drawals or exclusions are adequately explained with a flow chart
“No” if withdrawals or exclusions are not explained or accounted
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(Continued)
for. “Unclear” there is insufficient information to answer “yes” or
“no”
Could the patient flow have introduced bias? RISK: Low/High/Unclear
“No” if questions 1, 2, 3 and 4 are answered “yes” (Low risk)
“Yes” if any of the four questions is answered “no” (High risk)
“Unclear” if there is insufficient information to answer “yes” or
“no” (Unclear risk)
TcB: Transcutaneous bilirubin
TsB: Total serum bilirubin
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